 |
|
Guggulipid for the Treatment of Hypercholesterolemia
A Randomized Controlled Trial
Philippe O. Szapary, MD;
Megan L. Wolfe, BS;
LeAnne T. Bloedon, MS, RD;
Andrew J. Cucchiara, PhD;
Ara H. DerMarderosian, PhD;
Michael D. Cirigliano, MD;
Daniel J. Rader, MD
JAMA. 2003;290:765-772.
Context Herbal extracts from Commiphora mukul (guggul) have been widely used in Asia as cholesterol-lowering agents, and their popularity is increasing in the United States. Recently, guggulsterones, the purported bioactive compounds of guggul, have been shown to be potent antagonists of 2 nuclear hormone receptors involved in cholesterol metabolism, establishing a plausible mechanism of action for the hypolipidemic effects of these extracts. However, there are currently no published safety or efficacy data on the use of guggul extracts in Western populations.
Objective To study the short-term safety and efficacy of 2 doses of a standardized guggul extract (guggulipid, containing 2.5% guggulsterones) in healthy adults with hyperlipidemia eating a typical Western diet.
Design Double-blind, randomized, placebo-controlled trial using a parallel design, conducted March 2000-August 2001.
Participants and Setting A total of 103 ambulatory, community-dwelling, healthy adults with hypercholesterolemia in the Philadelphia, Pa, metropolitan area.
Intervention Oral, 3 times daily doses of standard-dose guggulipid (1000 mg), high-dose guggulipid (2000 mg), or matching placebo.
Main Outcome Measures Percentage change in levels of directly measured low-density lipoprotein cholesterol (LDL-C) after 8 weeks of therapy. Secondary outcome measures included levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, and directly measured very low-density lipoprotein cholesterol (VLDL-C), as well as adverse events reports and laboratory safety measures including electrolyte levels and hepatic and renal function.
Results Compared with participants randomized to placebo (n = 36), in whom levels of LDL-C decreased by 5%, both standard-dose guggulipid (n = 33) and high-dose guggulipid (n = 34) raised levels of LDL-C by 4% (P = .01 vs placebo) and 5% (P = .006 vs placebo), respectively, at 8 weeks, for a net positive change of 9% to 10%. There were no significant changes in levels of total cholesterol, HDL-C, triglycerides, or VLDL-C in response to treatment with guggulipid in the intention-to-treat analysis. While guggulipid was generally well tolerated, 6 participants treated with guggulipid developed a hypersensitivity rash compared with none in the placebo group.
Conclusions Despite plausible mechanisms of action, guggulipid did not appear to improve levels of serum cholesterol over the short term in this population of adults with hypercholesterolemia, and might in fact raise levels of LDL-C. Guggulipid also appeared to cause a dermatologic hypersensitivity reaction in some patients.
Author Affiliations: Department of Medicine (Drs Szapary, Cirigliano, and Rader, Mss Wolfe and Bloedon), Center for Experimental Therapeutics (Dr Rader, Mss Wolfe and Bloedon), General Clinical Research Center (Dr Cucchiara), and Center for Clinical Epidemiology and Biostatistics (Drs Szapary and Cucchiara), University of Pennsylvania School of Medicine, Philadelphia; Department of Biology & Medicinal Chemistry, University of the Sciences, Philadelphia (Dr DerMarderosian).
RELATED LETTERS
Guggulipid and Cholesterol Levels
Fabio Firenzuoli and Luigi Gori
JAMA. 2003;290(21):2800.
EXTRACT
| FULL TEXT
Guggulipid and Cholesterol Levels
Venkateswara Rao Karuparthy and Sreenivasarao Vepachedu
JAMA. 2003;290(21):2800-2801.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Hypolipidemic Agent Guggulsterone Regulates the Expression of Human Bile Salt Export Pump: Dominance of Transactivation over Farsenoid X Receptor-Mediated Antagonism
Deng et al.
J. Pharmacol. Exp. Ther. 2007;320:1153-1162.
ABSTRACT
| FULL TEXT
Complementary and Alternative Therapies for the Management of Dyslipidemia
Nies et al.
The Annals of Pharmacotherapy 2006;40:1984-1992.
ABSTRACT
| FULL TEXT
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:2020-2030.
ABSTRACT
| FULL TEXT
Guggulipid use in hyperlipidemia: Case report and review of the literature
Sahni et al.
Am J Health Syst Pharm 2005;62:1690-1692.
FULL TEXT
Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine)
Vogel et al.
J Am Coll Cardiol 2005;46:184-221.
FULL TEXT
The Ratio of Constitutive Androstane Receptor to Pregnane X Receptor Determines the Activity of Guggulsterone against the Cyp2b10 Promoter
Ding and Staudinger
J. Pharmacol. Exp. Ther. 2005;314:120-127.
ABSTRACT
| FULL TEXT
Guggul for hypercholesterolemia
Shields and Moranville
Am J Health Syst Pharm 2005;62:1012-1014.
FULL TEXT
The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand
Burris et al.
Mol. Pharmacol. 2005;67:948-954.
ABSTRACT
| FULL TEXT
Guggulsterone Activates Multiple Nuclear Receptors and Induces CYP3A Gene Expression through the Pregnane X Receptor
Brobst et al.
J. Pharmacol. Exp. Ther. 2004;310:528-535.
ABSTRACT
| FULL TEXT
Rhabdomyolysis Caused by Commiphora mukul, a Natural Lipid-Lowering Agent
Bianchi et al.
The Annals of Pharmacotherapy 2004;38:1222-1225.
ABSTRACT
| FULL TEXT
Guggulipid and Cholesterol Levels
Firenzuoli and Gori
JAMA 2003;290:2800-2800.
FULL TEXT
Guggulipid and Cholesterol Levels
Karuparthy and Vepachedu
JAMA 2003;290:2800-2801.
FULL TEXT
Herbal Extract Does Not Lower Cholesterol
Journal Watch Cardiology 2003;2003:2-2.
FULL TEXT
In brief
BMJ 2003;327:412-412.
FULL TEXT
Cardiovascular News
SoRelle
Circulation 2003;108
:e9012-e9013.
FULL TEXT
|
